CLDN18

Across TCGA pan-cancer cohorts, CLDN18 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLDN18 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLDN18 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLDN18 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where CLDN18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.708	0.366	<.001	67	view →
LUAD	DFS	Median	All	0.859	0.945	.021	12	view →
LSCC	OS	Median	All	0.924	1.000	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLDN18–PDAC (OS)

Open the PDAC breakdown →